Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Moderate-to-severe Chronic Plaque Psoriasis

In brief

This is a multi-regional, randomized, double-blind, placebo-controlled, clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SHR-1314 in adults with moderate-to-severe plaque psoriasis.

Key facts

Study ID

NCT03463187

Run by

Jiangsu HengRui Medicine Co., Ltd.

People needed

211

Starts

2017-12-15

Expected to finish

2020-08-31

Last updated by the study team

2023-08-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Elite Clinical Studies, LLC — Phoenix, Arizona, United States
• Anaheim Clinical Trials — Anaheim, California, United States
• Revival Research — Doral, Florida, United States
• Indago Research and Health Center - Emergency Medicine — Hialeah, Florida, United States
• Great Lakes Clinical Trials LLC — Chicago, Illinois, United States
• Clinical Partners, LLC — Johnston, Rhode Island, United States
• Center for Clinical Studies — Houston, Texas, United States
• Center for Clinical Studies — Webster, Texas, United States
• St George Dermatology and Skin Cancer Centre - Dermatology — Kogarah, New South Wales, Australia
• Westmead Hospital — Westmead, New South Wales, Australia
• Veracity Clinical Research Pty Ltd — Woolloongabba, Queensland, Australia
• Sinclair Dermatology - Dermatology — East Melbourne, Victoria, Australia
• Shanghai Huanshan Hospital Fudan University-Dermatology — Shanghai, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.